Sana Biotechnology, Inc. (SANA) Current Ratio
- Current ratio · latest quarter: Value 1.38×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.38× | Current assets / current liabilities. $170.63M ÷ $123.75M ≈ 1.38× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 170.63M USD | Assets, Current |
| Current obligations | 123.75M USD | Liabilities, Current |
| Cash and equivalents | 57.07M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 103.42M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 1.36M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $170.63M | $123.75M | $57.07M | $103.42M | (m) | (m) | $1.36M | (m) | 1.38× |
| 2026-03-31 | $111.69M | $86.27M | $83.80M | $17.34M | (m) | (m) | $2.12M | (m) | 1.29× |
| 2025-12-31 | $148.68M | $78.73M | $71.87M | $66.51M | (m) | (m) | $1.67M | (m) | 1.89× |
| 2025-09-30 | $161.76M | $35.51M | $103.36M | $49.70M | (m) | (m) | $1.86M | (m) | 4.55× |
| 2025-06-30 | $82.50M | $33.44M | $71.27M | $1.40M | (m) | (m) | $2.27M | (m) | 2.47× |
| 2025-03-31 | $112.73M | $33.16M | $96.13M | $8.57M | (m) | (m) | $989.00K | (m) | 3.40× |
| 2024-12-31 | $160.81M | $45.43M | $127.57M | $24.93M | (m) | (m) | $5.21M | (m) | 3.54× |
| 2024-09-30 | $210.15M | $47.00M | $127.00M | $72.01M | (m) | (m) | $2.99M | (m) | 4.47× |
| 2024-06-30 | $263.45M | $50.69M | $134.96M | $116.69M | (m) | (m) | $3.82M | (m) | 5.20× |
| 2024-03-31 | $321.26M | $52.90M | $177.05M | $134.03M | (m) | (m) | $6.09M | (m) | 6.07× |
| 2023-12-31 | $213.51M | $64.49M | $133.52M | $71.68M | (m) | (m) | $4.11M | (m) | 3.31× |
| 2023-09-30 | $279.52M | $66.64M | $168.45M | $100.12M | (m) | (m) | $9.93M | (m) | 4.19× |
| 2023-06-30 | $338.62M | $112.11M | $173.79M | $152.13M | (m) | (m) | $3.09M | (m) | 3.02× |
| 2023-03-31 | $369.91M | $102.78M | $160.46M | $188.85M | (m) | (m) | $2.33M | (m) | 3.60× |
| 2022-12-31 | $444.44M | $111.50M | $176.76M | $247.20M | (m) | (m) | $2.86M | (m) | 3.99× |
| 2022-09-30 | $500.25M | $114.81M | $163.34M | $322.41M | (m) | (m) | $3.99M | (m) | 4.36× |
| 2022-06-30 | $494.41M | $97.11M | $194.66M | $290.14M | (m) | (m) | $3.08M | (m) | 5.09× |
| 2022-03-31 | $523.22M | $93.51M | $188.52M | $323.86M | (m) | (m) | $4.76M | (m) | 5.60× |
| 2021-12-31 | $558.10M | $99.23M | $253.03M | $297.97M | (m) | (m) | $2.22M | (m) | 5.62× |
| 2021-09-30 | $612.85M | $92.01M | $433.67M | $170.04M | (m) | (m) | $3.95M | (m) | 6.66× |
| 2021-06-30 | $860.34M | $42.83M | $675.14M | $177.70M | (m) | (m) | $3.70M | (m) | 20.09× |
| 2021-03-31 | $967.47M | $35.15M | $750.69M | $209.55M | (m) | (m) | $4.26M | (m) | 27.52× |
| 2020-12-31 | $384.47M | $31.45M | $124.81M | $253.46M | (m) | (m) | $2.25M | (m) | 12.22× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |